A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibody- Associated vasculitis

Annals of the Rheumatic Diseases

Volumn 68, Issue 2, 2009, Pages 228-233

  Damoiseaux, J ^a   Dahnrich C ^b   Rosemann, A ^b   Probst, C ^b   Komorowski, L ^b   Stegeman, C A ^c   Egerer, K ^d   Hiepe, F ^d   Van Paassen, P ^a   Stocker W ^b   Schlumberger, W ^b   Tervaert, J W Cohen ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Institute of Experimental Immunology   (Germany)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOBLASTIN;

ANCA ASSOCIATED VASCULITIS; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MYELOBLASTIN; PROGNOSIS; RECOMBINANT PROTEINS; RECURRENCE; SENSITIVITY AND SPECIFICITY; VASCULITIS;

EID: 58849085096     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2007.086579     Document Type: Article

References (26)

1. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006;368:404-18.
2. Savige J, Gillis D, Benson E, Davies D, Esnault V, Falk RJ, et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 1999;111:507-13.
3. Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, et al. 1998. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998;53:743-53.
4. Choi HK, Liu S, Merkel PA, Colditz GA, Niles JL. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies. J Rheumatol 2001;28:1584-90.
5. Savige J, Dimech W, Fritzler M, Goeken J, Hagen EC, Jennette JC, et al. Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations fot testing in other autoimmune diseases. Am J Clin Pathol 2003;120:312-18.
6. Csemok E, Holle J, Hellmich B, Cohen Tervaert JW, Kallenberg CG, Limburg PC, et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. Rheumatology 2004;43:174-80.
7. Sun J, Fass DN, Viss MA, Hummel AM, Tang H, Homburger HA, et al. 1998. A proportion of proteinase 3 (PR3)-specific anti-neutrophil cytoplasmic antibodies (ANCA) only react with PR3 after cleavage of its N-terminal activation dipeptide. Clin Exp Immunol 1998;114:320-6.
8. Sun J, Fass DN, Hudson JA, Viss MA, Wieslander J, Homburger HA, et al. Capture- ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immunecomplexes. J Immunol Methods 1998;211:111-23.
9. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989;77:51-9.
10. Van Paassen P, Van Breda Vriesman PJ, Van Rie H, Cohen Tervaert JW. Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-The Limburg Renal Registry. Kidney Int 2004;66:909-13.
11. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187- 92.
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997:40:1725.
14. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
15. Boomsma MM, Damoiseaux JG, Stegeman CA, Kallenberg CG, Patnaik M, Peter JB, et al. Image analysis: a novel approach for the quantification of antineutrophil cytoplasmic antibody levels in patients with Wegener's granulomatosis. J Immunol Methods 2003;274:27-35.
16. Damoiseaux JG, Slot MC, Vaessen M, Stegeman CA, Van Paassen P, Cohen Tervaert JW. Evaluation of a new fluorescent-enzyme immuno-assay for diagnosis and follow-up of ANCA-associated vasculitis. J Clin Immunol 2005;25:202-8.
17. Damoiseaux J, Vaessen M, Knapen Y, Csernok E, Stegeman CA, Van Paassen P, et al. Evaluation of the FIDIS vasculitis multiplex immunoassay for diagnosis and follow- up of ANCA-associated vasculitis and Goodpasture's disease. Ann N Y Acad Sci 2007;1109:454-63.
18. Cohen Tervaert JW, Huitema MG, Hene RJ, Sluiter WJ, The TH, Van der Hem GK, et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990;336:709-11.
19. Stegeman CA, Cohen Tervaert JW, Sluiter WJ, Manson WL, De Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegenet granulomatosis. Ann Intern Med 1994;120:12-17.
20. Jenne DE, Kuhl A. Production and applications of recombinant proteinase 3, Wegener's autoantigen: problems and perspectives. Clin Nephrol 2006;66:153-9.
21. Rarok AA, Huitema MG, Van der Leij MJ, Van der Geld YM, Berthold H, Schmitt J, et al. Recombinant protein to analyze autoantibodies to proteinase 3 in systemic vasculitis. Am J Clin Pathol 2003;120:586-95.
22. Van der Geld YM, Oost-Kort W, Limburg PC, Specks U, Kallenberg CG. Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies. J Immunol Methods 2000;244:117-31.
23. Hellmich B, Csernok E, Fredenhagen G, Gross WL. 2007. A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3. Clin Exp Rheumatol 2007;25:S1-5.
24. Franssen CF, Stegeman CA, Kallenberg CG, Gans RO, De Jong PE. Hoorntje SJ, et al. Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Kidney Int 2000:57:2195-206.
25. Aries PM, Lamprecht P, Gross WL. Biological therapies: new treatment options for ANCA-associated vasculitis? Expert Opin Biol Ther 2007;7:521-33.
26. Rutgers A, Heeringa P, Damoiseaux JG, Cohen Tervaert JW. ANCA and anti-GBM antibodies in diagnosis and follow-up of vasculitic disease. Eur J Intern Med 2003;14:287-95.